Medtronic plc (MDT) Factsheet
Earnings-call transcript: none · IR deck: none — watch a real agent read these end-to-end →
Medtronic plc (MDT) Stock Analysis
Analysis from 10-Q filed 2026-09-03. Data as of Q3 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 7.0%. FCF margin 16.3%. D/E 0.6x. Source: 10-Q filed 2026-09-03.
| Metric | Value | Context |
|---|---|---|
| ROIC | 7.0% | Below expectations |
| FCF Margin | 16.3% | Strong cash generation |
| Debt/Equity | 0.6x | Moderate leverage |
ROIC 7.0% — Top 50% of sector peers. FCF margin 16.3% — Top 25%.
Explore Medtronic plc: Earnings History | Overview
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for MDT: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_section, get_metric_history, compare_companies, screen_filing_signals.
Profitability: Medtronic plc earns 7.0% ROIC, Top 50% in Healthcare
ROIC TTM 7.0%, sector median -7.7%, Top 50%. DuPont: NOPAT margin 14.4% × asset turnover 0.4x. Gross margin 65.0%. Operating margin 18.1%. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.0% | Warning | Above sector median of -7.7% |
| Return on Equity (ROE) | 10.7% | Adequate | Moderate equity returns |
| Gross Margin | 65.0% | Excellent | Strong pricing power |
| Operating Margin | 18.1% | Good | Efficient operations |
Cash Flow: Medtronic plc generates $6.1B FCF at 16.3% margin, positive NaN/8 quarters
FCF TTM $6.1B. FCF margin 16.3%, Top 25%. OCF/Net income 1.5x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 16.3% | Good | Excellent cash conversion |
| Free Cash Flow (TTM) | $6.1B | Good | Positive cash generation |
| OCF/Net Income | 1.5x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: Medtronic plc at 0.6x leverage, 9.4x interest coverage
Debt/Equity 0.6x. Total debt $28.2B, cash & investments $8.8B. Interest coverage 9.4x. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.6x | Good | Moderate leverage |
| Net Cash Position | $-19.3B | Warning | Net debt position |
| Interest Coverage | 9.4x | Good | Comfortable debt service |
Valuation: Medtronic plc trades at 24.7x earnings
P/E 24.7x. EV/Sales 4.0x. FCF yield 4.7%. Dividend yield 2.8%. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| P/E Ratio | 24.7x | Adequate | Premium valuation |
| EV/Sales | 4.0x | Good | Growth premium priced in |
| FCF Yield | 4.7% | Good | Lower cash yield |
| Dividend Yield | 2.8% | Adequate | Growth focus over income |
Capital Allocation: Medtronic plc returns 3.7% shareholder yield, reducing shares 0.1% YoY
Total shareholder yield 3.7% (div 2.8% + buyback 0.9%). Share count -0.1% YoY. Capital returned $4.8B TTM. Source: 10-Q filed 2026-09-03.
| Metric | MDT | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.7% | Good | Dividend + buyback yield combined |
| Buyback Yield | 0.9% | Adequate | Minimal buyback activity |
| Share Count Change (YoY) | -0.1% | Adequate | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $4.8B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.0% | Top 50% | - |
| Free Cash Flow Margin | 16.3% | Top 25% | 5.4x above |
| Gross Margin | 65.0% | Top 50% | 1.0x above |
| Operating Margin | 18.1% | Top 25% | - |
| Return on Equity (ROE) | 10.7% | Top 50% | - |
| P/E Ratio | 24.7x | N/A | - |
Financial Scorecard
| Metric | MDT | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.0% | Warning | Top 50% of sector (median: -7.7%) |
| Free Cash Flow Margin | 16.3% | Good | Top 25% of sector (median: 3.0%) |
| Gross Margin | 65.0% | Excellent | Top 50% of sector (median: 63.8%) |
| Debt to Equity Ratio | 56.0% | Good | Moderate leverage |
| P/E Ratio (Price-to-Earnings) | 24.7x | Adequate | Fair value |
| Free Cash Flow Yield | 4.7% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is Medtronic plc's Return on Invested Capital (ROIC)?
Medtronic plc (MDT) has a trailing twelve-month Return on Invested Capital (ROIC) of 7.0%. The 8-quarter median ROIC is 6.8% with a improving trend. Sector median -7.7%. Source: 10-Q filed 2026-09-03.
Q: What is Medtronic plc's Free Cash Flow Margin?
Medtronic plc (MDT) has a free cash flow margin of 16.3%, generating $6.1 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-09-03.
Q: What is Medtronic plc's P/E ratio and how does it compare to peers?
Medtronic plc (MDT) trades at a P/E ratio of 24.7x, which is above the sector median of N/A. EV/Sales 4.0x. FCF yield 4.7%. Source: 10-Q filed 2026-09-03.
Q: Does Medtronic plc pay a dividend?
Medtronic plc (MDT) currently pays a dividend yield of 2.8%. Total shareholder yield (dividend + buybacks) 3.7%. Source: 10-Q filed 2026-09-03.
Q: How much debt does Medtronic plc have?
Medtronic plc (MDT) has a debt-to-equity ratio of 0.6x with total debt of $28.2 billion. Interest coverage 9.4x. Net debt $19.3 billion. Source: 10-Q filed 2026-09-03.
Q: What is Medtronic plc's revenue and earnings growth?
Medtronic plc (MDT) grew revenue by 9.8% year-over-year. EPS +12.2% YoY. Source: 10-Q filed 2026-09-03.
Q: Is Medtronic plc buying back stock?
Medtronic plc (MDT) repurchased $1.2 billion of stock over the trailing twelve months. This represents a buyback yield of 0.9%. Share count -0.1% YoY. Source: 10-Q filed 2026-09-03.
Q: How does Medtronic plc compare to competitors in Healthcare?
Compared to other companies in Healthcare, Medtronic plc (MDT) shows: ROIC 7.0%, sector median -7.7% (Top 50%). FCF margin 16.3%, sector median 3.0% (Top 25%). Gross margin 65.0%, 1.2pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Medtronic plc?
No quantitative warning flags fired for Medtronic plc (MDT) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2026-09-03.
Data Source: Data sourced from 10-Q filed 2026-09-03. TTM metrics as of Q3 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms